Cargando…

Inflammasome Inhibitors

Detalles Bibliográficos
Autor principal:	Bertinaria, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625935/ https://www.ncbi.nlm.nih.gov/pubmed/34834004 http://dx.doi.org/10.3390/molecules26226912

Ejemplares similares

Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome
por: Pellegrini, Carolina, et al.
Publicado: (2021)

A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation
por: Pellegrini, Carolina, et al.
Publicado: (2018)

Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways
por: Mastrocola, Raffaella, et al.
Publicado: (2016)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Inflammasome-more Injury in Cholestasis
por: Zhao, Xiao, et al.
Publicado: (2020)

Inflammation, Inflammatory Diseases, and Inflammasomes
por: Yi, Young-Su
Publicado: (2023)

Inflammasome lights up in systemic sclerosis
por: Henderson, John, et al.
Publicado: (2017)

Editorial of Special Issue “Inflammasomes and Inflammation”
por: Yi, Young-Su
Publicado: (2022)

The NLRP3-Inflammasome in Health and Disease
por: Perri, Anna
Publicado: (2022)

Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades
por: Penna, Claudia, et al.
Publicado: (2020)

Inflamm-ageing or inflammasom-ageing as independent events
por: Cordero, Mario D., et al.
Publicado: (2020)

Complementary and Alternative Therapies Targeting Inflammasomes for Human Diseases
por: Yi, Young-Su, et al.
Publicado: (2020)

Role of NLRP3 inflammasome in inflammatory bowel diseases
por: Tourkochristou, Evanthia, et al.
Publicado: (2019)

Editorial of Special Issue “Roles of Inflammasomes and Methyltransferases in Inflammation”
por: Yi, Young-Su, et al.
Publicado: (2022)

Editorial of Special Issue “Regulatory Roles of Inflammasomes in Human Diseases”
por: Yi, Young-Su, et al.
Publicado: (2021)

Gain-of-Function Polymorphisms in Human Inflammasomes: Implications for Cystic Fibrosis
por: Jeansonne, Duane, et al.
Publicado: (2021)

Saturated fatty acid-crystals activate NLRP3 inflammasome
por: Karasawa, Tadayoshi, et al.
Publicado: (2019)

Fyn amplifies NLRP3 inflammasome signaling in Parkinson's disease
por: Panicker, Nikhil, et al.
Publicado: (2019)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome
por: Cantin, André M.
Publicado: (2019)

Fatty acid synthesis and NLRP3-inflammasome
por: Moon, Jong-Seok, et al.
Publicado: (2015)

“Inflammasome” Activity in Dialysis Patients: The Need to Go beyond Membrane Separation Mechanisms
por: Cozzolino, Mario, et al.
Publicado: (2022)

Kill Two Birds with One Stone: Role of the RIPK-3 in Necroptosis and Inflammasome Activation
por: Paudel, Sagar, et al.
Publicado: (2021)

SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?
por: Correale, Michele, et al.
Publicado: (2023)

Functional Role of Inflammasome Activation in a Subset of Obese Nonsmoking Patients with Severe Asthma
por: Ruggeri, Paolo, et al.
Publicado: (2019)

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
por: Mezzaroma, Eleonora, et al.
Publicado: (2021)

Boron-Based Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2017)

Tilting the Scales: Sirtuin 1 Favors Proinflammatory Macrophage Response Via Inflammasome Signaling and Metabolic Reprogramming
por: Kennedy, Lindsey
Publicado: (2022)

Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
por: Bahadoram, Mohammad, et al.
Publicado: (2021)

NLRP3 inflammasome and its inhibitors: a review
por: Shao, Bo-Zong, et al.
Publicado: (2015)

Inflammasome inhibitors: promising therapeutic approaches against cancer
por: Xu, Shengchao, et al.
Publicado: (2019)

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020)

Putting the Pieces Together: NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells
por: Andl, Claudia D.
Publicado: (2016)

NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked following SARS-CoV-2 Infection
por: Sergi, Consolato M.
Publicado: (2022)

Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models
por: Das, Biswadeep, et al.
Publicado: (2021)

Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2018)

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
por: Zhan, Xiaoyan, et al.
Publicado: (2023)

Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors
por: Thapa, Pritam, et al.
Publicado: (2023)

Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor
por: Gastaldi, Simone, et al.
Publicado: (2021)

Of inflammasomes and pathogens – sensing of microbes by the inflammasome
por: Bauernfeind, Franz, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_msvcf21h7hokdq5bfl0afu9gb5